AzTrials
AzTrials

TachyarrhythmiaNCT04863664

Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)

A study testing Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in people with Tachyarrhythmia, run by Medtronic Cardiac Rhythm and Heart Failure at 55 sites in 20 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next… Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Tachyarrhythmia
What is being tested?
Defibrillation (RV Implant) and Defibrillation (LBBAP Implant)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
998 participants
Where
55 sitesin 20 countries
Study dates
21 Jun 2021to 6 Nov 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

LEADR Inclusion Criteria:

  • Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:
  • de novo Medtronic CRT-D system implant
  • de novo Medtronic ICD system implant (single or dual chamber)
  • Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)
  • Subject is willing to undergo implant defibrillation testing if requested.
  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.

LEADR Exclusion Criteria:

  • Subject is unwilling or unable to personally provide Informed Consent.
  • Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).
  • Subject is contraindicated for ≤1 mg dexamethasone acetate.
  • Subject has a life expectancy of less than 12 months
  • For subject undergoing defibrillation testing the following medical conditions exclude them:
  • Pre-existing or suspected pneumothorax during implant
  • Current intracardiac left atrial or left ventricular (LV) thrombus
  • Severe aortic stenosis
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Unstable angina
  • Ejection Fraction less than 25%
  • Recent stroke or transient ischemic attack (within the last 6 months)
  • Known inadequate external defibrillation
  • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
  • Subject with any exclusion criteria as required by local law (e.g., age or other).
  • Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence
  • Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads
  • Subject with any evidence of active infection or undergoing treatment for an infection
  • Recent (or planned) cardiac surgery or stenting less than 1 month before implant
  • End stage renal disease
  • Subjects with NYHA IV classification
  • Subjects with a transplanted heart
  • Subjects with previously extracted leads
  • Subjects with Left Ventricular Assist Device

LEADR LBBAP Inclusion Criteria:

  • Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:
  1. De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)
  • Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.
  • Subject provides written authorization and/or consent per institution and geographical requirements.
  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up
  • Subject is willing to undergo implant defibrillation testing if requested

LEADR LBBAP Exclusion Criteria:

  • Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)
  • Subject is contraindicated for ≤1 mg dexamethasone acetate
  • Subject has a life expectancy of less than 12 months
  • For subject undergoing defibrillation testing the following medical conditions exclude them:
  • Pre-existing or suspected pneumothorax
  • Current intracardiac left atrial or LV thrombus
  • Severe aortic stenosis
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Unstable angina
  • Recent stroke or transient ischemic attack (within the last 6 months)
  • Known inadequate external defibrillation
  • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence
  • Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads
  • Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant
  • Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days
  • Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours
  • Subjects with end stage renal disease
  • Subjects with NYHA IV classification
  • Subjects with a transplanted heart or on the waiting list for a heart transplant
  • Subjects with previously extracted leads
  • Subjects with Left Ventricular Assist Device
  • Subjects that are vulnerable adults

Trial locations and contacts

55 sites in 20 countries.

55 sites in 20 countries

United States23 sites
  • LEADR: Presbyterian Heart Group

    Albuquerque, New Mexico, 87108

  • LEADR: Lehigh Valley Hospital - Cedar Crest

    Allentown, Pennsylvania, 18103

  • LEADR: Texas Cardiac Arrhythmia Research Foundation

    Austin, Texas, 78705

  • LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health

    Bay Shore, New York, 11030

  • LEADR & LEADR LBBAP: University of Virginia Medical Center

    Charlottesville, Virginia, 22903

  • LEADR: TriHealth Hatton Research Institute

    Cincinnati, Ohio, 45202

  • LEADR LBBAP: The Christ Hospital

    Cincinnati, Ohio, 45219

  • LEADR: Cleveland Clinic

    Cleveland, Ohio, 44195

  • LEADR LBBAP: The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210

  • LEADR: Texas Health Fort Worth Hospital

    Fort Worth, Texas, 76104

  • LEADR: Hartford Hospital

    Hartford, Connecticut, 06106

  • LEADR: Heart Center Research

    Huntsville, Alabama, 35801

  • LEADR: Saint Luke's Mid America Heart Institute

    Kansas City, Missouri, 64111

  • LEADR LBBAP: Aurora St. Luke's Hospital

    Milwaukee, Wisconsin, 53215

  • LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota, 55407

  • LEADR& LEADR LBBAP: Vanderbilt University medical Center

    Nashville, Tennessee, 37232

  • LEADR: Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • LEADR & LEADR LBBAP: Virginia Commonwealth University Health System

    Richmond, Virginia, 23298

  • LEADR: Washington University School of Medicine

    St Louis, Missouri, 63110

  • LEADR: University of South Florida

    Tampa, Florida, 33606

  • LEADR LBBAP: Torrance Memorial Medical Center

    Torrance, California, 90505

  • LEADR: Lourdes Cardiology Services

    Voorhees Township, New Jersey, 08034

  • LEADR LBBAP: Geisinger Wyoming Valley Medical Center

    Wilkes-Barre, Pennsylvania, 18711

Other trials in United States

Australia4 sites
  • LEADR: Ashford Hospital

    Ashford, South Australia, 8032

  • LEADR & LEADR LBBAP: The Prince Charles Hospital

    Chermside, Queensland, 4032

  • LEADR &LEADR LBBAP: Canberra Hospital

    Garran, 2605

  • LEADR & LEADR LBBAP: Royal Adelaide

    Norwood, South Australia, 5000

Other trials in Australia

Canada3 sites
  • LEADR: University of Calgary

    Calgary, Alberta, T2N 4N1

  • LEADR: Southlake Regional Health Centre

    Newmarket, Ontario, L3Y8C3

  • LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec

    Québec, Quebec, G1V 4G5

Other trials in Canada

France3 sites
  • LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord

    La Tronche, 38700

  • LEADR LBBAP: OC Santé - Clinique du Millénaire

    Montpellier, 34960

  • LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle

    Rouen, 76031

Other trials in France

Japan3 sites
  • LEADR & LEADR LBBAP: Kokura Memorial Hospital

    Kitakyushu, Fukuoka, 802-8555

  • LEADR: Tokyo Women's Medical University Hospital

    Shinjuku-Ku, Tokyo, 162-8666

  • LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center

    Suita, Osaka, 564-8565

Other trials in Japan

Spain3 sites
  • LEADR LBBAP: Hospital Universitario Virgen de las Nieves

    Granada, Granada, 18014

  • LEADR: Hospital Universitari Bellvitge

    L'Hospitalet de Llobregat

  • LEADR: Hospital Universitario y Politécnico La Fe

    Valencia, 46026

Other trials in Spain

China2 sites
  • LEADR & LEADR LBBAP: West China Hospital of Sichuan University

    Chengdu

  • LEADR: Shanxi Cardiovascular Hospital

    Taiyuan, Shanxi, 030000

Other trials in China

Hong Kong2 sites
  • LEADR & LEADR LBBAP: Queen Mary Hospital

    Hong Kong

  • LEADR: Princess Margaret Hospital

    Lai Chi Kok, 999077

Other trials in Hong Kong

Austria1 site
  • LEADR: Universitätsklinikum Krems

    Krems, Mitterweg, 3500

Other trials in Austria

Belgium1 site
  • LEADR LBBAP: Universitair Ziekenhuis Antwerpen

    Edegem, Antwerp, 2650

Other trials in Belgium

Denmark1 site
  • LEADR: Rigshospitalet

    Copenhagen, 2100

Other trials in Denmark

Germany1 site
  • LEADR: Klinikum Bielefeld Kardiologie

    Bielefeld, Bielefeld, 33604

Other trials in Germany

Italy1 site
  • LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII

    Bergamo, 24127

Other trials in Italy

Malaysia1 site
  • LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute

    Kuala Lumpur, 50400

Other trials in Malaysia

Netherlands1 site
  • LEADR LBBAP: Maastricht Universitair Medisch Centrum

    Maastricht, Limburg

Other trials in Netherlands

Poland1 site
  • LEADR LBBAP: Szpital Uniwersytecki w Krakowie

    Krakow

Other trials in Poland

Portugal1 site
  • LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology

    Carnaxide, 2790-134

Other trials in Portugal

Serbia1 site
  • LEADR: Klinicki Centar Srbije Pejsmejker centar

    Belgrade

Other trials in Serbia

Singapore1 site
  • LEADR: Ng Teng Fong General Hospital

    Singapore, Singapore

Other trials in Singapore

United Kingdom1 site
  • LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital

    London, W12 0HS

Other trials in United Kingdom

About this study

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.

The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.

Read the detailed description

The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (323 subjects enrolled).

Conditions
Tachyarrhythmia
Being tested
Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
Medical subject headings
Tachycardia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Defibrillation (RV Implant)Device

    Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

  • Defibrillation (LBBAP Implant)Device

    Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

Study groups in NCT04863664
Study groupRoleWhat they receive
Intervention/Treatment (LEADR)ExperimentalPatients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
Receives: Device: Defibrillation (RV Implant)
Intervention/Treatment (LEADR LBBAP)ExperimentalPatients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing
Receives: Device: Defibrillation (LBBAP Implant)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. LEADR: Estimate the rate of major Lead complication-free rate at 6 months

    Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.

    Measured: Implant to 6 Months

  2. LEADR: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead

    Defibrillation testing will be completed in a subset of subjects at implant.

    Measured: Day 1

  3. LEADR LBBAP: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead

    Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.

    Measured: Day 1

  4. LEADR LBBAP: The lead-related major complication rate at 3-months

    Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.

    Measured: Implant to 3 Months

Secondary outcomes (1)
  1. LEADR: Estimate the fracture-free rate of the Next Generation ICD lead

    Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.

    Measured: up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2021
  2. Study start21 Jun 2021
  3. Primary completion3 Sep 2025
  4. Study completion6 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
998 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04863664
Sponsor's protocol ID
MDT19004 / MDT22048
Status last verified
Apr 2025
First submitted
21 Apr 2021
Last updated
9 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Crossley GH 3rd, Mason PK, Hansky B, De Filippo P, Shah MJ, Philippon F, Sholevar D, Richardson TD, West MB, Dinerman J, Dawson J, Himes A, Severseike L, Thompson AE, Sanders P. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025 Feb;22(2):302-310. doi: 10.1016/j.hrthm.2024.09.005. Epub 2024 Sep 26.

    PubMed 39341436

Questions about this trial

What is this clinical trial studying?

A study testing Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in people with Tachyarrhythmia, run by Medtronic Cardiac Rhythm and Heart Failure at 55 sites in 20 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 55 sites in United States, Australia, Canada, France, Japan and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

LEADR: Estimate the rate of major Lead complication-free rate at 6 months (time frame: Implant to 6 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04863664, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in